Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label mass balance and pharmacokinetics study of [14C]-IMU-838 in healthy male subjects
NL-OMON51590Phase 1Completed
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vidofludimus calcium in multiple sclerosis (MS), sponsored by Immunic Therapeutics. Primary endpoint: Mass balance and elimination of [14C]-IMU-838. Started Jan 2023; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON51590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51590.